Macrogen
Macrogen is a Seoul-based publicly traded (KOSDAQ: 34450) genomics CRO founded in 1997, providing fee-for-service NGS, Sanger, microarray, single-cell, spatial, and proteomics analysis to 33,000+ research, pharma, clinical, and consumer customers across 153 countries, now pivoting toward AI precision medicine.
- Company typePublic
- Founded1997
- HeadquartersSeoul, South Korea
- Headcount251–500
- GTM typeB2B and B2C
- OfferingServices
What Macrogen does
Macrogen, Inc. is a Seoul-headquartered genomics and AI precision medicine company founded in 1997 and publicly listed on KOSDAQ (ticker 34450). The company provides fee-for-service genomic analysis to research institutions, pharmaceutical and biotech companies, healthcare providers, and direct-to-consumer customers across 153 countries, operating regional subsidiaries in Japan, Singapore, the Netherlands, Spain, Italy, France, Poland, Switzerland, the United States (Psomagen), and Chile. Its service portfolio spans the full multi-omics stack — next-generation sequencing (whole genome, exome, transcriptome, epigenome, metagenome, single-cell), capillary electrophoresis (Sanger) sequencing, microarray, oligo and gene synthesis, CRISPR model services, Olink proteomics, and spatial multi-omics — alongside clinical diagnostic services (PMG Lab NGS gene panels, cancer genome testing, GCLP-compliant clinical trial specimen analysis) and consumer brands GenTok and myPETGENE.
The underlying technology rests on 27+ years of accumulated sequencing know-how, 100PB+ of big-data computing infrastructure, and proprietary assets including the Korean Reference Genome AK1 (published in Nature, 2016). Macrogen claims CAPA Global Top 5 ranking by annual genome analysis volume, processes approximately 300,000 genomes per year, and holds the #1 domestic market share in Korea. The technology stack integrates instruments and reagents from a deep partner ecosystem (Illumina, Thermo Fisher, 10x Genomics, PacBio, Oxford Nanopore, Olink, Agilent, Ultima Genomics, Twist, Microsoft), and the company was the first global CRO to commit to deploying 10x Genomics Atera spatial biology instruments in 2026.
Revenue mechanics are predominantly transactional: per-base, per-reaction, per-sample, or quote-based project pricing for sequencing services, with multi-currency billing (USD, EUR, JPY, AUD, GBP, SGD) through a self-service LIMS platform (dna.macrogen.com) and regional enterprise field sales targeting large pharma and government contracts. The largest single revenue driver currently is the Korea National Integrated Bio Big Data Construction project (sole contractor; 145,952 WGS and 2,800 transcriptomes by 2026, scaling to 1 million Koreans by 2032). The company is transitioning its identity from a sequencing CRO toward an AI precision medicine platform, anchored by the Songdo Global Genome Center (completed June 2026), four internal R&D institutes (Bioinformatics, Biome, Syncgenes, Big Data Institute for Health), and selection for the national Agentic AI customized-care project in 2025.
Macrogen firmographics
Firmographics- Name
- Macrogen
- Legal name
- Macrogen, Inc.
- Website
- https://macrogen.com
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Macrogen is a Seoul-based publicly traded (KOSDAQ: 34450) genomics CRO founded in 1997, providing fee-for-service NGS, Sanger, microarray, single-cell, spatial, and proteomics analysis to 33,000+ research, pharma, clinical, and consumer customers across 153 countries, now pivoting toward AI precision medicine.
- Ownership category
- akta.pro rank
Macrogen industry classification
Industry- Product category
- Genomic Sequencing and Bioinformatics Services
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Microbiome & Metagenomics Services (HLAGANAH)
- akta.pro secondary industries
- Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Microbiome Diagnostics & Biomarker Platforms (gut/skin/oral/vaginal) (HLAAAFAH), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where Macrogen is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices15 records
Markets served
Macrogen business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- Fee-for-Service Genomic Sequencing and Analysis: Macrogen's primary revenue stream is fee-for-service genomic sequencing and analysis, encompassing NGS (Whole Genome, Exome, Transcriptome, Metagenome, Epigenome), CES/Sanger sequencing, microarray, and oligo/gene synthesis services billed per reaction, sample, or project.
- Clinical Diagnostic Services: Revenue from precision medicine cancer genome testing, NGS gene panel diagnostics (PMG Lab), and GCLP clinical trial sample analysis services, billed per test or contract.
- Personal Healthcare and Wellness Services: Direct-to-consumer genetic testing services (GenTok brand) for disease prediction, microbiome analysis, and pet genetic health testing, billed per test kit or analysis.
- Laboratory Consumables and Reagents: Sale of research reagents, labware, and related consumables supporting genomic research workflows.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Standard Oligo DNA Synthesis — priced per base (mer) |
| Unit Pricing | Pay-as-you-go | Modified Oligo Synthesis — priced per base plus modification fee |
| Unit Pricing | Pay-as-you-go | RNA Oligo Synthesis — priced per base |
| Unit Pricing | Pay-as-you-go | Custom Peptide Synthesis — priced per peptide based on length and purity |
| Unit Pricing | Pay-as-you-go | CES (Sanger) Sequencing Services — priced per reaction or plate |
| Usage-based | Pay-as-you-go | NGS Services — project-based quotation |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Macrogen product offering
Product offeringCore offering
Macrogen is a global genomics and AI healthcare company that provides fee-for-service genomic sequencing, multi-omics analysis, and bioinformatics interpretation. Its portfolio spans NGS (whole genome, exome, transcriptome, epigenome, metagenome), CES/Sanger sequencing, microarray, proteomics (Olink), gene and oligo synthesis, single-cell and spatial multi-omics, and clinical diagnostics including cancer genome testing and GCLP-compliant clinical trial analysis. It also operates consumer genetic testing platforms (GenTok, myPETGENE) and runs AI-driven disease prediction models integrating genomic, clinical, and lifestyle data.
Product overview
Macrogen is a global genomics and AI healthcare company offering a comprehensive suite of genomic analysis services organized around three core pillars: research analysis services, clinical diagnostic services, and consumer health platforms. The research portfolio includes NGS-based services (Whole Genome Sequencing, Whole Exome Sequencing, Transcriptome Sequencing, Epigenome Sequencing, Metagenome Sequencing), CES/Sanger sequencing, microarray services, proteomics (Olink), gene synthesis, oligo synthesis, CRISPR/model animal services, single-cell multi-omics, spatial multi-omics, and microbiome analysis. The clinical division provides precision medicine cancer services, cancer genome testing with NGS gene panels (PMG Lab), and GCLP-compliant clinical trial specimen analysis. Consumer-facing services include GenTok direct-to-consumer genetic testing and myPETGENE pet healthcare. The company operates R&D institutes (Bioinformatics, Biome, Syncgenes, Big Data) and strategic facilities including the Songdo Global Genome Center AI precision medicine hub. Recent launches include deployment of the 10x Genomics Atera spatial biology platform (2026) and a Singapore genomics laboratory via PacBio partnership (2025).
Differentiator
Problem solved
Functional benefit
Brands
- Psomagen: US subsidiary of Macrogen providing genomic analysis services as a global CRO
- GenTok (젠톡)
- myPETGENE ID
- Songdo Global Genome Center
- PMG Lab
Products and services
- Whole Genome Sequencing DNA sequencing service that reads and analyzes the entire genome, including Whole Genome De novo Sequencing for new species and Whole Genome Resequencing for variation analysis such as SNP, InDel, CNV, and structural variation, for research institutions and pharma clients.
- Whole Exome Sequencing Selective analysis of exon regions where genes are located, providing a cost-effective alternative to whole genome resequencing for gene variation analysis in research and clinical research contexts.
- Transcriptome Sequencing RNA sequencing service for gene expression profiling, novel transcriptome discovery, fusion gene detection, and alternative splicing variant analysis, including mRNA, single-cell RNA, small RNA, and exosomal RNA sequencing, for researchers.
- Epigenome Sequencing Sequencing service analyzing DNA methylation and histone acetylation patterns, including Whole Genome Bisulfite Sequencing and Methyl-Capture Sequencing, for epigenetic mechanism research in academic and commercial settings.
- Metagenome Sequencing
- CES (Capillary Electrophoresis Sequencing) Sanger DNA sequencing service including Standard Sequencing, Difficult Sequencing, Primer Walking, and EZ-Seq, along with identification services, fragment analysis, and customized sequencing, for researchers globally with per-reaction pricing.
- Microarray Services DNA microarray-based gene expression, SNP genotyping, CGH for copy number variation, and DNA methylation analysis using Illumina, Affymetrix, and Agilent platforms, for research and clinical research clients.
- Proteomics (Olink) High-sensitivity protein analysis service using Olink technology for biomarker discovery and protein expression profiling, integrated with genomic and transcriptomic data for multi-omics research clients.
- Gene Synthesis DNA gene synthesis service synthesizing genes in plasmid DNA state with free cloning, 100% sequence guarantee via ABI 3730xl, and additional mutagenesis services, for researchers requiring custom genetic constructs.
- Oligo Synthesis DNA, RNA, and peptide oligo synthesis service with automated processes, various modification options, and quality control via MALDI-TOF mass spectrometry, for research laboratories globally.
- CRISPR/Model Animal Services CRISPR Knock-in/out services, genetically engineered mouse (GEM) models, mass production, and mouse model services for academic and pharmaceutical research applications.
- Single Cell Multi-omics Analysis Single-cell level analysis of gene expression enabling analysis of thousands of transcription bodies simultaneously, including B cell and T cell full-length clonotype analysis, for translational and discovery research.
- Spatial Multi-Omics Analysis In situ spatial biology analysis for whole-transcriptome spatial analysis at single-cell sensitivity, including the 10x Genomics Atera platform deployment, supporting fresh-frozen and FFPE tissue samples for discovery and translational research.
- Precision Medicine (Cancer) Cancer risk prediction, cancer cause analysis, and cancer monitoring services based on genomic information integrated with medical and lifestyle data, for hospitals and clinical partners.
- Cancer Genome Testing Comprehensive cancer genetic testing including cancer gene panels, hereditary cancer susceptibility testing, BRCA1/2 testing, and gastric cancer panel, for hospitals and healthcare providers.
- NGS Gene Panel Laboratory (PMG Lab)
- GCLP Clinical Trial Specimen Analysis
- Personal Healthcare (GenTok)
- Pet Healthcare (myPETGENE)
- Microbiome Analysis Service
Quantifiable outcome
- Annual genome analysis capacity of 300,000 genomes per year
- +3 more outcomes
Companies that use Macrogen
Customer profileNamed customers10 records
Segments5 records
Ideal customer profiles5 records
Macrogen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Macrogen partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and major.
- 10x GenomicscoreMacrogen and its US subsidiary Psomagen committed to deploying multiple 10x Genomics Atera instruments as the first global CRO/service provider to adopt the Atera spatial biology platform, enabling whole-transcriptome spatial analysis at scale for discovery and translational research. Commercial shipments expected in H2 2026.
- Ultima GenomicscoreMacrogen and Ultima Genomics jointly held a symposium in Seoul to promote AI genomic analysis and the development of an integrated BioAI ecosystem. The event focused on leveraging the UG200 platform to reduce costs and increase efficiency in genomic data production and analysis for personalized medicine and disease prediction.
- Pacific Biosciences (PacBio)corePacific Biosciences partnered with A*STAR and Macrogen Inc. to launch a high-precision genomics laboratory in Singapore. The partnership aims to advance precision medicine research in the Asia-Pacific region, leveraging PacBio SMRT sequencing technology alongside Macrogen's genomic analysis capabilities.
- IlluminamajorIllumina is listed as a global partner logo on Macrogen's website. Macrogen uses Illumina platforms including NovaSeq X plus, NovaSeq 6000, HiSeq X ten, HiSeq 4000, HiSeq 2500, NextSeq 500, and MiSeq for various NGS applications.
- Thermo Fisher ScientificmajorThermo Fisher Scientific is listed as a global partner logo on Macrogen's website. Macrogen utilizes Thermo Fisher platforms for various sequencing and analysis applications.
- OlinkmajorOlink is listed as a global partner logo. Macrogen offers Olink-based high-sensitivity proteomics analysis services, providing biomarker discovery and protein biomarker analysis.
- AgilentmajorAgilent is listed as a global partner logo. Macrogen uses Agilent platforms including SurePrint G3 Gene Expression, SurePrint G3 Exome microarrays, and Agilent CGH microarrays for gene expression and copy number variation analysis.
- Oxford Nanopore TechnologiesmajorOxford Nanopore Technologies is listed as a global partner logo. Macrogen leverages nanopore sequencing technology for long-read genomic analysis applications.
- A*STAR (Agency for Science, Technology and Research, Singapore)coreA*STAR partnered with Pacific Biosciences and Macrogen to launch a high-precision genomics laboratory in Singapore, advancing precision medicine research in the Asia-Pacific region within the Singapore National Precision Medicine programme.
- DNA LinkmajorDNA Link is a consortium partner with Macrogen, Teragen Biotech, and CZEN Biovitz in Korea's National Integrated Bio Big Data Construction project, led by the Ministry of Health and Welfare and Korea Disease Control and Prevention Agency.
- Teragen BiotechmajorTeragen Biotech is a consortium partner with Macrogen, DNA Link, and CZEN Biovitz in Korea's National Integrated Bio Big Data Construction project, responsible for producing genomic and transcriptomic data for 1 million Koreans.
- CZEN BiovitzmajorCZEN Biovitz is a consortium partner with Macrogen, DNA Link, and Teragen Biotech in Korea's National Integrated Bio Big Data Construction project.
Scale indicators8 records
Recent moves7 records
Expansion highlights5 records
Macrogen competitors and assessment
Company assessmentDirect peers
- BGI Group: Largest global genomic sequencing service provider with massive population-genomics project experience (e.g., Chinese Million Genomes). Directly competes with Macrogen on NGS services, NIPT and clinical genomics, and on government-scale population genomics contracts across Asia.
- Novogene: Global NGS services CRO offering whole genome, exome, transcriptome and single-cell sequencing from facilities in the US, Europe and China. Directly comparable to Macrogen's core fee-for-service NGS portfolio and target academic/biopharma customer base.
- Azenta Life Sciences (formerly GENEWIZ): Provides genomic services including Sanger/NGS, gene synthesis and oligo synthesis globally from US, European and Asian labs. Overlaps with Macrogen's CES, oligo and gene synthesis product lines and similar pharma/biotech customer base.
- Eurofins Genomics: Global genomics services arm of Eurofins Scientific offering NGS, Sanger, microarray, oligo synthesis and synthetic biology services. Directly comparable fee-for-service genomics portfolio and customer segments across Europe, US and Asia.
- Personalis: US-based NGS services company specializing in whole-genome sequencing for immuno-oncology clinical trials and biopharma customers. Comparable on pharma GCLP/clinical-trial specimen analysis and on pushing into AI-driven molecular diagnostics.
- Integrated DNA Technologies (IDT, Danaher): Major provider of custom oligonucleotides, gene synthesis and NGS library prep reagents/services. Directly overlaps with Macrogen's oligo synthesis, gene synthesis and reagent product lines, particularly in the US and European research market.
Broad incumbents
- Illumina: Dominant NGS instrument and reagent provider whose platforms (NovaSeq, NextSeq) underpin most of Macrogen's service volume. Increasingly a broad incumbent offering its own population-genomics and clinical sequencing services, posing both partner and competitive risk.
- Tempus AI: AI-driven precision medicine company combining multi-modal data with sequencing and analytics for oncology. Comparable to Macrogen's AI precision medicine and cancer genome testing ambitions, but operating at much larger scale in the US market.
- Foundation Medicine (Roche): Clinical genomics leader offering comprehensive genomic profiling for oncology. Comparable to Macrogen's PMG Lab cancer genome testing and NGS gene panel business, particularly for pharma companion-diagnostic and clinical-trial biomarker programs.
Emerging players
- Twist Bioscience: Synthetic DNA and NGS target-enrichment provider serving pharma, biotech and academic customers. Overlaps with Macrogen's gene/oligo synthesis and emerging NGS panel services, and is itself a Macrogen technology partner.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Macrogen social profiles
Digital presenceMacrogen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Macrogen leadership team
Management profileNumber of profiles
Profiles4 records
Macrogen subsidiaries and ownership
Company hierarchySubsidiaries6 records
Macrogen funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Macrogen M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Macrogen
What does Macrogen do?
Macrogen is a global genomics and AI healthcare company that provides fee-for-service genomic sequencing, multi-omics analysis, and bioinformatics interpretation. Its portfolio spans NGS (whole genome, exome, transcriptome, epigenome, metagenome), CES/Sanger sequencing, microarray, proteomics (Olink), gene and oligo synthesis, single-cell and spatial multi-omics, and clinical diagnostics including cancer genome testing and GCLP-compliant clinical trial analysis. It also operates consumer genetic testing platforms (GenTok, myPETGENE) and runs AI-driven disease prediction models integrating genomic, clinical, and lifestyle data.
Is Macrogen a public or private company?
Macrogen is a public company. It is classified as public and is currently operating.
When was Macrogen founded?
Macrogen was founded in 1997. It employs 251 to 500 people.
Where is Macrogen based?
Macrogen is headquartered in Seoul, South Korea, in the Asia region.
How does Macrogen make money?
Four revenue lines are on record. Fee-for-Service Genomic Sequencing and Analysis are the primary driver. The others are clinical Diagnostic Services, personal Healthcare and Wellness Services and laboratory Consumables and Reagents.
Who are Macrogen's main competitors?
Direct peers on record are BGI Group, Novogene, Azenta Life Sciences (formerly GENEWIZ), Eurofins Genomics, Personalis and Integrated DNA Technologies (IDT, Danaher). Broad incumbents are Illumina, Tempus AI and Foundation Medicine (Roche). Twist Bioscience is listed as an emerging player.
Does Macrogen have an API?
No public API is recorded for Macrogen.
What industry is Macrogen in?
Macrogen's product category is Genomic Sequencing and Bioinformatics Services. Its primary akta.pro industry code is HLAGANAH, Microbiome & Metagenomics Services, with a secondary code of HLAAANAA, Genomic Profiling & Sequencing-Based Precision Medicine. Its NAICS code is 621511 and its SIC code is 8071.